| Returns | 1W : -10.3% , 1M : -14.3%,1Y : 26.2% |
| Peers & Returns | 1W | 1M | 1Y |
| AUROBINDO PHARMA | -10.3% | -14.3% | 26.2% |
| SUN PHARMACEUTICAL INDUSTRIES | -7.2% | -7.5% | 20.6% |
| DRREDDYS LABORATORIES | -5.7% | 13.2% | 85.8% |
| DIVIS LABORATORIES | -9.7% | -5.5% | 94.2% |
| CIPLA | -9.2% | -2% | 67.1% |
| PIRAMAL ENTERPRISES | -11.7% | -16.8% | -33.1% |
| LUPIN | -9.8% | 0.1% | 33.8% |
| TORRENT PHARMACEUTICALS | -7.8% | -3.8% | 59.2% |
| CADILA HEALTHCARE | -8.1% | -3.3% | 59.2% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
25.77 3.47 3.2 2.45 |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
27% 20% 37% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.29 0.4 0.37 0.35 |
0.33 0.5 0.41 0.41 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
6.17 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
-5.54% 8.05% 10% -1.43% |
11.07% 87.82% 121.52% 116.24% |
| QtrlyTrend |
4
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
